In 1991, the National Institutes of Health.[17] listed 167 symptoms
and reasons to avoid the use of aspartame , but today it is a multi-million
dollar business that contributes to the degeneration of the human
population, as well as the deliberate suppression of overall intelligence,
short-term memory[18] and the added contribution as a carcinogenic
environmental co-factor. The FDA and the Centers for Disease Control
continue to receive a stream of complaints from the population about
aspartane. It is the only chemical warfare weapon available in mass
quantities (should keep the cone-heads happy) on the grocery shelf
and promoted in the media. It has also been indicated that women
with an intolerance for phenylalinine, one of the compoents of aspartame,
may give birth to infants with as much as a 15% drop in intelligence
level if they habitually consume products containing this dangerous
substance.[19]
FAA Collusion in Suppression of Facts on Aspartame
The March 1995 issue of The Pacific Flyer published a pro-aspartame
article in which it stated, "the Federal Aviation Administration
conducted its own cognitive research and, according to experts,
found no contraindications that would prevent pilots, or anyone,
from ingesting aspartame." This flies in the face of consistent
reports from pilots who maintain they have suffered severe and dangerous
repercussions in the air after drinking soft drinks containing aspartame.
Virtually every time, symptoms disappeared when aspartame-laced
drinks were discontinued.[20] Over 600 pilots have reported this
problem.
FDA "Findings" on Aspartame Remain Based on Faked
Tests
So, the faked Searle tests remain. The FDA bases its findings on
the faked Searle tests, and the Journal of the American Medical
Association, examining the FDA findings, based on the faked Searle
tests, announced "the consumption of aspartame poses no health
risk for most people." Searle officials argue that the use
of aspartame as an artificial sweetener "has been officially
approved not only by the FDA, but by foreign regulatory agencies
and the World Health Organization" - based on Searle-sponsored
aspartame research, not independently conducted tests.
Symptoms of Aspartame Intoxication: Minimal to Severe
The symptoms of aspartame intoxication include severe headaches,
nausea, vertigo, insomina, loss of control of limbs, blurred vision,
blindness, memory loss, slurred speech, mild to severe depression
often reaching suicidal levels, hyperactivity, gastrointestinal
disorders, seizures, skin lesions, rashes, anxiety attacks, muscle
and joint pain, numbness, mood changes, loss of energy, menstrual
cramps out of cycle, hearing loss or ringing in the ears, loss or
change of taste, and symptoms similar to those in a heart attack.
In addition, aspartic acid chelates (combines) with chromium - which
is a necessary element for proper operation of the thyroid gland.
People who consume large quantities of aspartame may end up with
a false diagnosis of Graves disease and suffer allopathic irradiation
of their thyroid gland for no reason. Complaints about aspartame
represent 80-85% of all food complaints registered with the FDA.
More than 6,000 complaints have been made concerning the effects
of aspartame. Thirty independent doctors and scientists have conducted
research on the adverse effects of aspartame or have compiled supporting
data against its use.The use of NutraSweet® or Equal® should
be seriously curtailed or stopped.
Aspartame Use Part of Planetary Biomedical Genocide
The fact that tons of aspartame is pumped into the world population
each year, knowingly and deliberately, especially with the historical
and documented record of fraud and misrepresentation, constitutes
a conspiracy of the highest order, as well as criminal negligence.
The rewards of continued use are increased profits for the medical
and pharmaceutical industries and chemical companies who produce
aspartame and treat people suffering from the effect of it. Aspartame
is the only biochemical warfare product on grocery shelves. And,
the band plays on ....
The artificial sweetener aspartame is said by some commentators
to be the most fully tested and safest food additive in industrial
history. Because it is a dipeptide of two familiar and essential
amino acids, namely aspartic acid and phenylalanine, there are prima
facie reasons for thinking that it should be safe. It is, moreover,
one of the most successful synthetic chemicals every produced. The
dominant producer is the Nutrasweet Corporation (a subsidiary of
Monsanto), and a recently published estimate suggested that world
sales amounted to approximately $1,000 million in 1995.(1)
Doubts about the safety of this compound have, however, surfaced
repeatedly during its turbulent history, and a particularly serious
set of fresh doubts have recently emerged in a paper in the journal
Neuropathology and Experimental Neurology, focusing on the possibility
that aspartame might be contributing to the increasing incidence
of brain cancer.(2)
Prof. John Olney of Washington University St Louis and his colleagues
have based their hypothesis on several sets of considerations. Firstly,
they analyzed the cancer statistics gathered by the US National
Cancer Institute from catchment areas representing approximately
10% of the US population for the period since 1975. They found that
the introduction of aspartame into the USA, into dry goods in 1981
and soft drinks in 1983, was followed by an abrupt increase (of
approximately 10%) in the reported incidence of brain tumors. The
change was most noticeable between 1984 and 1985, and it corresponded
to approximately 1,500 extra cases of brain cancer per year in the
USA.
Their second main finding is that there has also been a marked
change in the incidence of particular types of brain tumors, with
a reduction in the proportion of a relatively nonaggressive (and
often preliminary) type of tumor (astrocytomas) and a sharp increase
in the incidence of a far more aggressive (and all too often terminal)
type of tumor (glioblastomas).
The investigators argue, moreover, that the reported changes in
tumor incidence were unlikely to have been artefacts of improvements
in diagnostic technologies. The introduction and rapid diffusion
of computerised tomography in the early to mid- 1970s, and of magnetic
resonance imaging technology in the early to mid-1980s, certainly
improved diagnostic precision. But they contend that the impact
of those innovations upon the reported incidence of these central
nervous system (CNS) tumors had fully worked their way through before
aspartame was introduced.
Before these imaging technologies were introduced, it was far harder
to diagnose brain cancer. Consequently, it was often not until tumors
developed into glioblastomas that they were diagnosed, and a relatively
high portion of tumors at the earlier astrocytoma stage went undetected.
When the imaging technologies were introduced, brain tumors tended
to be detected at the earlier stage, and consequently in the late
1970s the number of reported astrocytomas went up, while the number
of glioblastomas exhibited a corresponding decline.
After aspartame was introduced, however, the opposite pattern can
be found. The incidence of glioblastomas rose sharply, and starting
in the late 1980s the number of astrocytomas declined even more
sharply. Since those latter changes run counter to the direction
which could be attributed to the introduction of better diagnostic
technologies, it is hard to see how the reported changing tumor
incidence could be ascribed to innovations in diagnosis. If the
apparent increase in overall incidence had been due to improved
diagnostics, then we should expect a marked change in post- diagnostic
survival rates, but no such change was evident.
Olney and his colleagues suspect aspartame to be implicated in
the aetiology of the extra cases of brain cancer for three main
reasons. Firstly, the type of CNS tumor found to be increasing most
rapidly in the USA is the same kind of lesion as was found in one
of the animal studies conducted on aspartame in the 1970s.(3) Indeed,
when the safety of aspartame was considered by a Public Board of
Inquiry in 1980, it recommended against the approval of aspartame
primarily because of a concern that aspartame appeared to be a brain
carcinogen in rodents. A team of scientists at the US Food and Drug
Administration concurred with the judgement of the Board, and they
too recommended that further studies be conducted to clarify the
issue before aspartame could be considered acceptably safe for use.
Both the Public Board of Inquiry and the FDA staff scientists were,
however, over-ruled by the incoming FDA Commissioner, Arthur Hull
Hayes, who asserted that the brain cancer risk was minimal and that
further research was not necessary.
Olney and his colleagues have also drawn attention to the results
of a study by Shephard et al published in 1993.(4) Shephard and
her colleagues attempted to simulate in vitro the conditions that
can occur in the human digestive tract, and in particular the conditions
which result in the nitrosation of dietary ingredients. They reported
that the nitrosated aspartame had significant mutagenic action.
That evidence may be important because it suggests not only a mechanism
through which aspartame could exert a possible carcinogenic action,
but also why the interval between the compound's introduction and
the elevation of brain cancer rates appears to have been so brief.
Olney et al also suggest that aspartame may reasonably be suspected
of responsibility because the other main candidates for responsibility,
such as ionising radiation, smoke inhalation, pesticides, electromagnetic
fields and various other chemicals were gradually introduced over
recent decades rather than all at once in the early 1980s. Exposures
to those potential hazards are, furthermore, occupationally linked
and it is hard to see how they could explain why males and females
seem to be equally affected.
If Olney's hypothesis is to be substantiated it will be necessary
to analyse several long-term brain cancer time- series data sets
for other countries covering the period both before and since aspartame
was introduced. That has proved difficult because while aggregate
brain cancer statistics are readily available, information on tumors
types is hard to obtain. If aspartame were to act by modifying an
already present or nascent brain cancer, we should expect its impact
to vary in different countries in ways which depend on the age structure
of the consumers of this sweetener. Anecdotal evidence suggests
that a larger proportion of 50 to 70 year old Americans consume
aspartame-sweetened products than is the case in the UK or in other
European countries. An alternative approach might therefore entail
conducting new long-term animal feeding studies, but their relevance
to humans is endlessly contestable.
While Olney and his colleagues have raised complex questions about
the safety of aspartame, other questions have previously been raised
without having been fully answered. The manner in which no fewer
than 15 of the initial safety tests were conducted and reported
during the 1970s has been repeatedly criticised. An FDA task force
showed, for example, that in one particular study it was impossible
to identify the occasion on which a particular animals had died.
As the report says: "Observation records indicated that animal
A23LM was alive at week 88, dead from week 92 through week 104,
alive at week 108, and dead at week 112."(5) That represented
just one of 52 significant shortcomings in the conduct and reporting
of just one of those 15 studies. Those studies have, moreover, never
been repeated.
Several commentators have therefore argued that unless and until
those 15 pivotal studies are repeated, no-one can be in a position
confidently to assert that aspartame is safe. In the mid-to-late
1980s, a series of reports started to emerge suggesting that aspartame
is capable of acute adverse reactions in a small proportion of sensitive
consumers. The symptoms reported include headaches and blurred vision
at the most mild through to epileptic-type seizures at the most
severe.
The accumulation of evidence, concerning both acute and chronic
hazards, now poses a substantial problem for both regulatory officials
and for the general public. The challenge for policy-makers, as
ever, is to decide how much evidence is sufficient to support a
judgement that something is either sufficiently safe or that it
poses a significant hazard. A decision of that sort, in relation
to an artificial sweetener, will depend on a judgement about the
balance of benefits and risks. It is, however, quite hard to demonstrate
that artificial sweeteners are beneficial to any group other than
diabetics. The period since the early 1980s has seen a rapid rise
in the consumption of artificial sweeteners, but there has been
no corresponding decline in the consumption of sugar, either in
the USA, the UK or in the European Union as a whole. That implies
that, in aggregate, artificial sweeteners are not acting as sugar
substitutes but merely as supplements to sugar consumption.
Many of the products containing artificial sweeteners are labelled
as 'diet' products implying that consuming artificially sweetened
products helps people to control or even to reduce their weight.
There is however no reliable evidence to indicate that artificial
sweeteners actually help people loose weight. On the contrary, the
bulk of the available evidence suggests that in relation to attempted
weight loss, artificial sweeteners are at best ineffective and at
worst counter-productive. There is, in particular, evidence that
artificial sweeteners are appetite stimulants, and while a particular
mouthful of artificially sweetened food or drink may contain fewer
calories than their sugar-sweetened analogues, the consumption of
artificial sweeteners may provoke people into going on, what might
be termed, 'a calorie hunt'.
If the likely benefits and risks of aspartame are to be properly
explored, and if consumers are to be properly informed and protected,
these complex issues need to be explored in a comprehensive and
open fashion, and not behind closed doors, be they in Whitehall,
in the European Commission in Brussels or at the World Health Organisation's
office in Geneva. The public are entitled to be sure, in particular,
that none of the experts advising the authorities are acting as
paid consultants to the companies which either manufacture or utilise
artificial sweeteners. Neither the Ministry of Agriculture, Fisheries
and Food nor the Department of Health, nor the European Commission
nor even the WHO can provide such an assurance.